Feuerstein questions Stemline's use of message board posts


Shares of Stemline Therapeutics (STML) are off 4% in premarket trading in the face of a rather negative article by TheStreet's Adam Feuerstein.

Feuerstein discusses the company's use of posts from a message board (hosted by the Leukemia and Lymphoma Society) in its investor slide deck.

The article questions the appropriateness of leaving out certain passages of the posts when using them in the investor presentation.

Feuerstein also says "a donor lymphocyte infusion" may have contributed to the complete remission of one patient being treated with SL-401, a possibility the company acknowledged as "within the realm of possibility."

For more on SL-401, see here.

Comments (1)
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
     
    Nice hit piece (the original story). Seems the stock shurgged it off. That has to be a solid trading indicator (I've been long since 36).
    4 Dec 2013, 06:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs